Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 696-003-5 | CAS number: 924726-92-1
Endpoint summary
Administrative data
Description of key information
GSK2609973A is not considered to be acutely toxic based upon results obtained with similar materials.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A package of occupational toxicology tests and pharmacological screening assays have been completed for GSK2609973A. Functional receptor screening tests have also been conducting with this compound in order to understand its potential for interaction with the human glucocorticoid receptor.
The conclusion of the assessment relies primarily upon read across from structurally-related substances with the package of occupational toxicology tests providing data to support this approach. This is consistent with international guidelines for read across of toxicological data (1, 2).
1. European Chemicals Agency, Guidance on information requirements and chemical safety assessment 1. Chapter R.6: QSARs and grouping of chemicals, Guidance for the Implementation of REACH.May 2008
2. OECD, Series on Testing and Assessment, Number 80, Guidance on Grouping of Chemicals, September 2007
Justification for classification or non-classification
Taking account of the small package of studies with GSK2609973A and close structural similarity to substances for which a more complete dataset exists, it is considered justified to use a read-across approach to address any outstanding data-gaps for this material. Based upon the outcome of this read across approach it is considered that there are no major toxicological issues that have been identified for GSK2609973A.
GSK2609973A is not considered to be acutely toxic based upon results obtained with similar materials, as follows:
Not expected to be toxic if ingested.
Based upon data for a wide spectrum of substances with steroidal structures and read across from CCI12778, significant acute toxicity potential is not expected with GSK2609973A.
Not expected to be toxic if inhaled.
Not expected to be toxic following contact with skin.
• Low toxicity expected based upon lack of steroidal activity and comparison with similar substances.
• CCI12778 (9,11-Epoxide) produced no evidence of irritation in an acute dermal irritation study in a single rabbit.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
